105 related articles for article (PubMed ID: 38722190)
1. Chronic Prurigo.
Thünemann J; Müller S; Steinbrink K; Ständer S; Zeidler C
J Dtsch Dermatol Ges; 2024 Jun; 22(6):813-823. PubMed ID: 38722190
[TBL] [Abstract][Full Text] [Related]
2. Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.
Müller S; Zeidler C; Ständer S
Am J Clin Dermatol; 2024 Jan; 25(1):15-33. PubMed ID: 37717255
[TBL] [Abstract][Full Text] [Related]
3. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
Liao V; Cornman HL; Ma E; Kwatra SG
Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of biologics in prurigo nodularis.
Müller S; Bieber T; Ständer S
Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
[TBL] [Abstract][Full Text] [Related]
5. A critical evaluation of nemolizumab for prurigo nodularis.
Brooks SG; Yosipovitch G
Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
Nilforoushzadeh MA; Heidari N; Ghane Y; Heidari A; Hajikarim-Hamedani A; Hosseini S; Jaffary F; Najar Nobari M; Tavakolzadeh P; Najar Nobari N
Inflammopharmacology; 2024 Apr; 32(2):991-1003. PubMed ID: 38332383
[TBL] [Abstract][Full Text] [Related]
8. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
9. [Update on the treatment of chronic prurigo].
Zeidler C; Pereira MP; Ständer S
Dermatologie (Heidelb); 2022 Aug; 73(8):614-619. PubMed ID: 35925236
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and treatment algorithm for chronic nodular prurigo.
Ständer HF; Elmariah S; Zeidler C; Spellman M; Ständer S
J Am Acad Dermatol; 2020 Feb; 82(2):460-468. PubMed ID: 31310842
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
12. Chronic prurigo.
Misery L
Br J Dermatol; 2022 Oct; 187(4):464-471. PubMed ID: 35656799
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.
Chiricozzi A; Maurelli M; Gori N; Argenziano G; De Simone C; Calabrese G; Girolomoni G; Peris K
J Am Acad Dermatol; 2020 Jul; 83(1):39-45. PubMed ID: 32229281
[TBL] [Abstract][Full Text] [Related]
14. A critical review of dupilumab for adult patients with prurigo nodularis.
Biazus Soares G; Yosipovitch G
Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
[TBL] [Abstract][Full Text] [Related]
15. Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options.
Frølunde AS; Wiis MAK; Ben Abdallah H; Elsgaard S; Danielsen AK; Deleuran M; Vestergaard C
Dermatology; 2022; 238(5):950-960. PubMed ID: 35417906
[TBL] [Abstract][Full Text] [Related]
16. Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment.
Gründel S; Pereira MP; Storck M; Osada N; Schneider G; Ständer S; Zeidler C
Acta Derm Venereol; 2020 Sep; 100(16):adv00269. PubMed ID: 32556359
[TBL] [Abstract][Full Text] [Related]
17. Learning from nemolizumab: A promising therapy for prurigo nodularis.
Kim BS
J Allergy Clin Immunol; 2024 Jun; 153(6):1548-1549. PubMed ID: 38460679
[No Abstract] [Full Text] [Related]
18. Dupilumab for prurigo nodularis: Case series and review of the literature.
Holm JG; Agner T; Sand C; Thomsen SF
Dermatol Ther; 2020 Mar; 33(2):e13222. PubMed ID: 31917498
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
20. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
